An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy
Pharmacology, Toxicology and Pharmaceutical Science
2
7%
Agricultural and Biological Sciences
2
7%
Social Sciences
2
7%
Other
2
7%
Unknown
17
57%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 November 2020.
All research outputs
#18,764,674
of 23,257,423 outputs
Outputs from Journal of Medical Economics
#1,089
of 1,510 outputs
Outputs of similar age
#315,311
of 420,759 outputs
Outputs of similar age from Journal of Medical Economics
#30
of 47 outputs
Altmetric has tracked 23,257,423 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,510 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,759 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
